MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Minerva Neurosciences Total Shareholders Equity 2011-2026 | NERV
Annual Total Shareholders Equity Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -141 M | -25.7 M | -28.5 M | -20 M | 7.98 M | 52.7 M | 27.8 M | 90.3 M | 132 M | 106 M | 55.3 M | 51.5 M | 20.2 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -141 M | 25.3 M |
Quarterly Total Shareholders Equity Minerva Neurosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.6 M | -32.1 M | -29.1 M | -25.7 M | -21.7 M | -44.5 M | -36.6 M | -28.5 M | -20 M | -12.5 M | -26.6 M | -20 M | -14.2 M | -8.38 M | -736 K | 7.98 M | 28.1 M | 36.2 M | 45.4 M | 52.7 M | 52.7 M | 52.7 M | 52.7 M | 27.8 M | 27.8 M | 27.8 M | 27.8 M | 90.3 M | 90.3 M | 90.3 M | 90.3 M | 132 M | 132 M | 132 M | 132 M | 106 M | 106 M | 106 M | 106 M | 55.3 M | 55.3 M | 55.3 M | 55.3 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 20.2 M | 20.2 M | 20.2 M | - | 19 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -44.5 M | 36.9 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 209.63 | -0.71 % | $ 371 B | USA |
 |
Verastem
VSTM
|
57.2 M | $ 4.99 | -5.77 % | $ 346 M | USA |
 |
VistaGen Therapeutics
VTGN
|
70.4 M | $ 0.57 | -5.85 % | $ 17.6 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Voyager Therapeutics
VYGR
|
196 M | $ 3.96 | -4.24 % | $ 232 M | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
219 M | $ 12.36 | -11.46 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
518 M | $ 6.39 | 3.06 % | $ 1.08 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
7.4 M | $ 2.78 | -0.71 % | $ 4.73 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
XBiotech
XBIT
|
140 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
755 M | $ 54.44 | -1.96 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
13.7 M | $ 5.41 | -2.87 % | $ 868 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
186 M | $ 4.07 | -5.57 % | $ 172 M | USA |
 |
Xencor
XNCR
|
636 M | $ 11.4 | -7.43 % | $ 846 M | USA |
 |
XOMA Corporation
XOMA
|
83.9 M | $ 29.93 | -1.97 % | $ 362 M | USA |
 |
22nd Century Group
XXII
|
15.8 M | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
23.6 M | $ 1.06 | -2.75 % | $ 21.7 M | Israel |
 |
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | USA |